202 related articles for article (PubMed ID: 2091733)
1. Biochemical basis for the activity and selectivity of oral antifungal drugs.
Vanden Bossche H; Marichal P; Gorrens J; Coene MC
Br J Clin Pract Suppl; 1990 Sep; 71():41-6. PubMed ID: 2091733
[TBL] [Abstract][Full Text] [Related]
2. Anti-Candida drugs--the biochemical basis for their activity.
Vanden Bossche H; Willemsens G; Marichal P
Crit Rev Microbiol; 1987; 15(1):57-72. PubMed ID: 3319421
[TBL] [Abstract][Full Text] [Related]
3. Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors.
Vanden Bossche H; Marichal P
Am J Obstet Gynecol; 1991 Oct; 165(4 Pt 2):1193-9. PubMed ID: 1951574
[TBL] [Abstract][Full Text] [Related]
4. Biochemical approaches to selective antifungal activity. Focus on azole antifungals.
Vanden Bossche H; Marichal P; Gorrens J; Coene MC; Willemsens G; Bellens D; Roels I; Moereels H; Janssen PA
Mycoses; 1989; 32 Suppl 1():35-52. PubMed ID: 2561184
[TBL] [Abstract][Full Text] [Related]
5. Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs.
Venkateswarlu K; Denning DW; Kelly SL
J Med Vet Mycol; 1997; 35(1):19-25. PubMed ID: 9061581
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance to azole antifungals.
Marichal P; Vanden Bossche H
Acta Biochim Pol; 1995; 42(4):509-16. PubMed ID: 8852341
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antifungal activity of statin-azole associations as witnessed by Saccharomyces cerevisiae- and Candida utilis-bioassays and ergosterol quantification.
Cabral ME; Figueroa LI; Fariña JI
Rev Iberoam Micol; 2013 Jan; 30(1):31-8. PubMed ID: 23069981
[TBL] [Abstract][Full Text] [Related]
8. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis.
Vanden Bossche H; Ausma J; Bohets H; Vermuyten K; Willemsens G; Marichal P; Meerpoel L; Odds F; Borgers M
Antimicrob Agents Chemother; 2004 Sep; 48(9):3272-8. PubMed ID: 15328084
[TBL] [Abstract][Full Text] [Related]
9. Effect of different inhibitors of sterol biosynthesis on both fungal growth and aflatoxin production.
Fanelli C; Fabbri AA; Brasini S; De Luca C; Passi S
Nat Toxins; 1995; 3(2):109-13. PubMed ID: 7613735
[TBL] [Abstract][Full Text] [Related]
10. Suppression of ATP in Candida albicans by imidazole and derivative antifungal agents.
Odds FC; Cheesman SL; Abbott AB
Sabouraudia; 1985 Dec; 23(6):415-24. PubMed ID: 3913012
[TBL] [Abstract][Full Text] [Related]
11. Antifolates as antimycotics? Connection between the folic acid cycle and the ergosterol biosynthesis pathway in Candida albicans.
Navarro-Martínez MD; Cabezas-Herrera J; Rodríguez-López JN
Int J Antimicrob Agents; 2006 Dec; 28(6):560-7. PubMed ID: 17046206
[TBL] [Abstract][Full Text] [Related]
12. Terconazole. Pharmacology of a new antimycotic agent.
Cauwenbergh G; Vanden Bossche H
J Reprod Med; 1989 Aug; 34(8 Suppl):588-92. PubMed ID: 2677363
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology.
Meerpoel L; Backx LJ; Van der Veken LJ; Heeres J; Corens D; De Groot A; Odds FC; Van Gerven F; Woestenborghs FA; Van Breda A; Oris M; van Dorsselaer P; Willemsens GH; Vermuyten KJ; Marichal PJ; Vanden Bossche HF; Ausma J; Borgers M
J Med Chem; 2005 Mar; 48(6):2184-93. PubMed ID: 15771461
[TBL] [Abstract][Full Text] [Related]
14. [Synthesis and antifungal activity of 1-(1,2,4-triazolyl-1H-1-yl)-2-(2,4-diflurophenyl)-3-(4-substituted benzyl-1-piperazinyl)-2-propanols].
Sheng CQ; Zhang WN; Ji HT; Song YL; Yang S; Zhou YJ; Zhu J; Lü JG
Yao Xue Xue Bao; 2003 Sep; 38(9):665-70. PubMed ID: 14730915
[TBL] [Abstract][Full Text] [Related]
15. Ergosterol biosynthesis inhibition: a target for antifungal agents.
Barrett-Bee K; Dixon G
Acta Biochim Pol; 1995; 42(4):465-79. PubMed ID: 8852337
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and antifungal activity of triazole and benzotriazole derivatives.
Rezaei Z; Khabnadideh S; Pakshir K; Hossaini Z; Amiri F; Assadpour E
Eur J Med Chem; 2009 Jul; 44(7):3064-7. PubMed ID: 18760508
[TBL] [Abstract][Full Text] [Related]
17. New and prospective developments in antifungal drugs.
Cauwenbergh G
Acta Derm Venereol Suppl (Stockh); 1986; 121():147-53. PubMed ID: 3012922
[TBL] [Abstract][Full Text] [Related]
18. [Attack point of ergosterol biosynthesis. Drugs and pharmacology].
Bracher F
Pharm Unserer Zeit; 2003; 32(2):118-23. PubMed ID: 12677964
[No Abstract] [Full Text] [Related]
19. Antifungal agents: mode of action in yeast cells.
Carrillo-Muñoz AJ; Giusiano G; Ezkurra PA; Quindós G
Rev Esp Quimioter; 2006 Jun; 19(2):130-9. PubMed ID: 16964330
[TBL] [Abstract][Full Text] [Related]
20. A novel method for studying ergosterol biosynthesis by a cell-free preparation of Aspergillus fumigatus and its inhibition by azole antifungal agents.
Ballard SA; Ellis SW; Kelly SL; Troke PF
J Med Vet Mycol; 1990; 28(4):335-44. PubMed ID: 2176688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
